Growth and nutrition in children with Ataxia telangiectasia by Stewart, Emma et al.
1 
 
Title Page: 
Title: Growth and Nutrition in Children with Ataxia Telangiectasia 
 
Corresponding author: 
Dr Jayesh M Bhatt 
Consultant Respiratory Paediatrician 
Nottingham Children’s hospital 
National Paediatric Ataxia Telangiectasia clinic 
QMC, Derby Road 
Nottingham 
United Kingdom 
NG7 2UH 
0115 9249924 x 64041 
Fax: 0115 9709 006 
Jayesh.bhatt@nuh.nhs.uk 
 
Full names, institutions, city, and country of all co-authors: 
Dr Emma Stewart 
Nottingham Children’s hospital 
National Paediatric Ataxia Telangiectasia clinic 
QMC, Derby Road 
Nottingham 
United Kingdom 
NG7 2UH 
2 
 
 
Dr Andrew P. Prayle 
University of Nottingham, 
School of Clinical Science, 
Queens Medical Centre, 
Child Health, 
Nottingham, 
United Kingdom 
NG7 2UH 
 
Ms Alison Tooke 
Nottingham Children’s hospital 
National Paediatric Ataxia Telangiectasia clinic 
QMC, Derby Road 
Nottingham 
United Kingdom 
NG7 2UH 
 
Ms Sara Pasalodos 
Nottingham Clinical Genetics Service, 
National Paediatric Ataxia Telangiectasia clinic 
Clinical Genetics Service 
City Hospital Campus 
The Gables 
3 
 
Gate 3 Hucknall Road 
Nottingham 
United Kingdom 
NG5 1PB 
 
Dr Mohnish Suri 
Nottingham Clinical Genetics Service, 
National Paediatric Ataxia Telangiectasia clinic 
Clinical Genetics Service 
City Hospital Campus 
The Gables 
Gate 3 Hucknall Road 
Nottingham 
United Kingdom 
NG5 1PB 
 
Professor Andy Bush 
Professor of Paediatrics and Head of Section (Paediatrics), Imperial College 
Professor of Paediatric Respirology, National Heart and Lung Institute 
Consultant Paediatric Chest Physician, Royal Brompton & Harefield NHS Foundation Trust 
Sydney Street, 
London 
United Kingdom 
SW3 6NP 
4 
 
 
Keywords: Ataxia Telangiectasia, growth, nutrition, respiratory infections, 
immunodeficiency 
 
Word count: 2526 (excluding title page, abstract, references, figures and tables). 
  
5 
 
Funding statement: This research received no specific grant from any funding agency in the 
public, commercial or not-for-profit sectors. 
 
Acknowledgements: 
AB was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal 
Brompton and Harefield NHS Foundation Trust and Imperial College London. 
APP was supported by a NIHR ACL. 
 
Contributorship statement: 
JB, ES, AP, AT, SP, AB made substantial contributions to the conception or design of the 
work, or the acquisition, analysis or interpretation of data. 
ES, AP, MS, SP, AB, and JB: Drafting the work or revising it critically for important intellectual 
content. 
JB, AB: Final approval of the version published. 
 
 
  
6 
 
Abstract 
Background: Ataxia Telangiectasia (A-T) is a rare multisystem disease with high early mortality 
from lung disease and cancer. Nutritional failure adversely impacts outcomes in many 
respiratory diseases. Several factors influence nutrition in children with A-T. We hypothesised 
that children with A-T have progressive growth failure and that early gastrostomy tube 
feeding (percutaneous endoscopic gastrostomy, or PEG) is a favourable management option 
with good nutritional outcomes.  
Methods: Data were collected prospectively on weight, height and body mass index (BMI) at 
the national paediatric A-T clinic. Adequacy and safety of oral intake was assessed. Nutritional 
advice was given at each multidisciplinary review. 
Results: 101 children (51 girls) had 222 measurements (32 once, 32 twice, 24 thrice) between 
2009 and 2016. Median (range) age was 9.3 (1.5 to 18.4) years. Mean (sd) weight, height and 
BMI Z-scores were respectively -1.03(1.57), -1.17 (1.18) and -0.36 (1.43). 35/101 children had 
weight Z-scores below -2 on at least one occasion.  Weight, height and BMI Z-scores declined 
over time. Decline was most obvious after 8 years of age. 14/101 (13.9%) children had a PEG, 
with longitudinal data available for 12. In a nested case control study, there was a trend for 
improvement in weight in those with a PEG (p = 0.06).  
Conclusions: A-T patients decline in growth over time. There is an urgent need for new 
strategies, including an understanding of why growth falters. We suggest early proactive 
consideration of PEG from age 8 years onwards in order to prevent progressive growth failure. 
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What is known about this topic: 
Small cross sectional studies have shown that children with A-T have poor nutritional status. 
Patients with A-T die prematurely, the leading causes of death being respiratory diseases 
and cancer 
Growth failure adversely impacts outcomes in many respiratory diseases. 
 
What this study adds: 
Progressive growth failure becomes apparent in nearly a quarter of the children with Ataxia 
Telangiectasia around 8 years of age. 
70% of these children improved their weight Z-score after institution of gastrostomy feeding.  
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Background 
Ataxia Telangiectasia (A-T) is a rare autosomal recessive disease, caused by mutations in the 
ATM (Ataxia-Telangiectasia mutated) gene. This gene encodes a protein kinase, ATM, which 
is responsible for the cellular response to double stranded DNA breaks (1). A-T causes 
progressive ataxia, immunodeficiency, sinopulmonary infections, oculocutaneous 
telangiectasia, increased cancer risk and increased sensitivity to therapeutic doses of ionising 
radiation (1). The most reliable estimates for the number of people with A-T, in the UK at 
least, are 3 per million (2) and, it is estimated that 150 families are affected, with 
approximately 170 cases of A-T in the UK and Ireland (Professor AMR Taylor, School of Cancer 
Sciences, University of Birmingham, UK; personal communication)). The median survival is 25 
years (3) ;, the leading causes of premature death being respiratory diseases and cancer (4). 
Undernutrition adversely affects lung health. Poor nutritional status and decreased 
pulmonary function have been shown to be linked in other diseases, including Cystic Fibrosis 
(CF) (5,6). Worsening nutritional status increases infection-related morbidity and mortality 
(7). Malnutrition  is  of  particular  concern  in children since  it adversely  affects  not  only  
normal accrual of height and weight  but  may also impact lung  development (8).  
Small cross-sectional studies have shown that patients with A-T exhibit high rates of 
malnutrition, short stature and reduced lean body mass (9–12). Numerous factors including 
neurodegeneration, limited food intake with progressive disease, dysphagia and/or 
swallowing incoordination, limited physical activity,  hormonal changes, hypogonadism, 
insulin resistance, glucose intolerance, abnormal expression of IGF1 (somatomedin C), low 
levels of IGFBP3 (insulin-like growth factor binding protein-3), and infections and an 
associated hyper-catabolic state all potentially contribute to poor growth (9,13). A-T causes 
extreme insulin resistance (14), but clinical diabetes is diagnosed infrequently (15–17) and it 
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is unclear whether the presence of diabetes also affects nutritional status and lung disease. 
Oropharyngeal dysphagia with aspiration is common and is progressive in older patients 
(second decade) with A-T. The onset of dysphagia coincides with a decrease in nutritional 
status, although in a cross sectional study it is not possible to distinguish between nutritional 
deficiency as a cause or effect of dysphagia (18). Hence, it is important to maintain good 
nutrition in children with A-T to protect respiratory function and to ensure normal growth.  
We hypothesised that children with A-T have progressive growth failure and that early 
percutaneous endoscopic gastrostomy feeding (PEG) improves nutritional outcomes. We 
aimed longitudinally to assess the growth of children with A-T and to examine the effect of 
PEG insertion on their growth.      
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Methods 
Between May 2009 and April 2016, 101 children (51 girls) attended the national paediatric A-
T clinic in Nottingham. Each child participated in multidisciplinary consultations, including a 
dietician, speech and language therapist, occupational therapist, neuromuscular and 
respiratory physiotherapist, respiratory paediatrician, neurologist, immunologist, geneticist, 
and clinical psychologist. All children were diagnosed with A-T based on the WHO criteria (19). 
They are recalled for review at the clinic every two years or earlier if there are clinical 
concerns. The clinic records the age, height, weight and body mass index (BMI) of each child 
at every visit. Additional measurements were available in some children from their local 
clinics. It is also noted whether the child has a PEG in situ or has been referred for PEG 
insertion. The indications for PEG insertion were not protocol driven at the time of this 
analysis, but was a clinical decision taken individually for each patient after discussion with 
parents, either at the national clinic or at the local hospital by the local team, or both. Ethical 
approval was not required for this study as anthropometric data were recorded as per 
standard paediatric clinical care and any management advice was based on the clinical 
evaluation at the time of the assessment. 
These data were collected prospectively in clinic by the respiratory paediatrician. In addition, 
retrospective data were taken from dieticians’ letters from each clinic. This included the 
dieticians’ recommendations for continuing support as required. The dieticians used a four 
tiered system of nutritional advice. The first level was standard nutritional advice. Second was 
fortification of food, for example, with full-fat milk and butter. Nutritional supplements were 
then recommended if the child’s growth continued to falter. Finally, PEG feeding would be 
advised if there is ongoing growth failure despite appropriate caloric intake and fortification. 
This was occasionally preceded by a short trial period of nasogastric tube feeding. Z-scores 
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(standard deviation scores) were then calculated for BMI, height-for-age and weight-for-age, 
using WHO criteria (20). Z-scores below -2.0 mean the child is wasted, stunted or underweight 
(21),  below -3.0  severely wasted, stunted or underweight.  
Statistics 
The study reports on all patients seen at the National Children’s Ataxia Telangiectasia clinic, 
therefore a power calculation was inappropriate. We investigated the effect of age and 
presence of a PEG upon weight Z-score. Using all the measurements per patient, a growth 
curve analysis of all patients was undertaken, comparing models with and without a fixed 
effect of age upon Z-score.   
Patients who had a PEG inserted were matched with control(s) by age and weight Z-score. We 
took the first weight measurement for each child with a PEG (or, for children with only one 
measurement with a PEG, the measurement immediately prior to this), and subtracted this 
from the final measurement in our dataset to give a change in weight over time for each 
patient with a PEG. We matched each of these cases with at least one control. Controls had 
age at baseline of less than 1 year away from the case, and were within one unit of Z-score 
from the case at baseline. We compared the trajectory of weight gain / loss over time with a 
sign test.   
Data were analysed with R (22) (version 3.2.1 using the lme4 (23) package to fit the growth 
curve models). Full methods including illustrative code are available from the authors on 
request.   
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Results 
 Of the 101 children that attended the clinic, 32 children had one set of measurements, 32 
had two, 24 had three, 11 had four and two had five. Weight was recorded in all patients at 
every visit, a total of 222 measurements. Height and BMI were recorded 216 times (97%). The 
median and range of age, Z-scores for weight, height and BMI and the number of 
measurements that were underweight, stunted or wasted can be seen in Table 1, which 
shows a significant proportion had Z-scores below -2. In total, 35/101 patients were 
underweight (Z-score weight less than -2), and 73/101 were stunted (height Z-score less than 
-2) on at least one occasion.   
The trajectory of Z-scores for patients is shown in figure 1, with separate plots for weight, 
height and BMI. On inspection, the relationship appeared non-linear over time with a possible 
increase in the rate of decline in mid-childhood. A growth curve model was fitted to model 
weight Z-scores, using a random intercept for slope and intercept, with a linear fixed effect 
for age. The rate of decline of weight Z-score was 0.1 units per year (95% confidence interval: 
-0.15 to -0.04; ANOVA comparing models with and without the fixed effect: p = <0.01).  This 
indicates that compared, to a healthy population, weight decreased year on year by 0.1 
standard deviations (i.e. the weight was low, and became increasingly lower).   
Longitudinal data were available for 25 underweight children. Of these, 10 had a PEG inserted, 
and of these 10, 7 improved their weight Z-score (figure 1B). Overall, of the 12 children for 
whom we have serial measurements of weight and a PEG was inserted, 9/12 improved their 
Z-score, for two there is currently only one measurement post PEG insertion (thus limited 
follow up), and only one patient with a PEG declined in PEG weight Z-score on serial 
measurement post PEG insertion.   
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Twelve children with a PEG had multiple measurements, and we matched these children with 
25 cases. Cases and controls are compared in Table 2. The mean change in weight Z-score 
after insertion of a PEG during follow up was 0.175 (sd 1.37), whereas for controls this was -
0.384 (sd 0.93); sign test p = 0.06. 
Discussion 
We showed that there is a clinically important and statistically significant decline in weight 
and height Z-scores over time. Despite regular dietician advice, fortification of food and 
prescription of nutritional supplements we have found that approximately 1/4 of our clinic 
patients were defined as underweight and/or stunted at some point during the study period 
(Z-scores less than -2).   
The plots of individual trends in weight, height and BMI suggested that PEG insertion was 
associated with an improvement in weight Z-score. We used a nested case control study, 
matching at least two controls for every case in which a PEG was inserted, and for whom we 
had multiple measurements of weight. We took the first weight after PEG insertion (or the 
weight immediately prior to this if we only had one weight after PEG insertion) and found that 
patients with a PEG had on average weight gain, whereas controls without a PEG tended to 
lose weight. When comparing our data for weight Z-scores with each visit (Table 1) we found 
that between visit 1 (median age 8.3 years) and visit 3 (median age 12.3) there is an obvious 
drop in Z-scores.  We suspect that the drop in weight Z-score appears to commence at around 
the 8th birthday.  
Nutritional failure and poor growth are well recognised in A-T.  Voss et al (9) found that 25% 
(N=6) patients whose height was below the below the 3rd percentile were in the 2 to 9-year-
old age group. In this younger age group, the A-T patients showed significantly lower levels of 
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Insulin-like growth factor-1 IGF-1 compared with healthy controls which was not seen in the 
older age group. IGF-BP3 levels in A-T patients were also lower compared with the controls in 
both age groups. They concluded that A-T patients exhibit growth retardation as well as 
GH/IGF-1 deficiency. In a small Australian study which assessed nutritional status by 
measuring body cell mass (BCM) (12), 3 out of 4 children who had height Z-scores of -2 or less, 
were less than 9 years of age. Ehlayel et al (24) studied 13 patients with A-T (age 7.7 ± 3.5 
years , range: 3–14.5 years) and found height SDS of −1.4 ± 1.2 with 38% of them having a 
score < −2. 31% of the patients had low BMI and 38 % had low IGF-1. Thus stunting in A-T 
appears to start in early childhood.   
The high number of underweight and stunted children in comparison to those with low BMI 
highlights one of the disadvantages of using BMI as a nutritional measure. Those who are both 
short and thin may have a BMI within the normal range. A recent study using BCM found a 
much higher incidence of malnutrition (69%) that included children who were considered 
overweight by traditional measures. This may be reflected in the high proportion (47-48%) of 
children in this study that decreased their BMI centile over time. 
 The proportion of PEGs (13.9%) in our cohort is identical to another large published series 
(14.6%) (25). Early PEG placement in A-T (26) and other neurological conditions (27,28) is 
beneficial in terms of safety and caregiver satisfaction. Late placement is associated with poor 
outcomes, thought to be due to factors including advanced lung disease and malnutrition 
(26).  Given the rarity of A-T, extrapolation from other conditions is inevitable. In children with 
CF, clinical audit (29) and a structured nutritional intervention approach (30) (with early 
referral for PEG in those with severe malnutrition) improved outcomes in terms of growth 
parameters, lung function and the 2-year survival post-PEG insertion improved from 70% to 
100%. The long-term nutritional benefit of PEG tube placement is critically dependent on pre-
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surgical pulmonary function with better growth if PEGs are placed early when the child has 
better pulmonary function (31). 
A key strength of our study is the size in comparison to other A-T cohorts; we reported all 101 
patients seen, and a total of 222 measurements, thus removing sampling bias. We are 
therefore able to provide relatively robust estimates of the rate of decline over the whole 
cohort.  However, even though this is a large study in the field of A-T, overall the numbers are 
low, and so we have limited statistical power.   
A clear limitation of our study is that patients received PEGs driven by perceived clinical need; 
this was neither protocolised nor part of a randomised controlled trial.  Clinical need is shown 
by the baseline weight Z-score in our cases (mean –2.42) versus controls (-1.21).  An 
observational study such as this can only be hypothesis generating, and the findings of 
apparent benefit require prospective testing.  Moreover, given our limited numbers, we 
cannot say for certain that a PEG is definitely associated with an increased rate of growth in 
those patients where one was inserted, though we have limited support for this from our 
nested case – control study.  As PEG insertion is a rare intervention in an extremely rare 
disorder, we believe that finding robust evidence (e.g. randomised clinical trial data) for its 
efficacy in A-T would be extremely challenging, and a RCT is unlikely to ever be performed 
due to clear feasibility difficulties. However, as many of our patients weight Z-scores improve 
with insertion of a PEG, this suggests that growth failure is not an inevitable consequence of 
A-T, but a complication that may be successfully managed with early intervention. It would 
be useful to know about the interactions between pulmonary function (often not measured 
because of coordination difficulties) and nutrition. Whether early PEG improves lung function 
and mortality in A-T is an important question for future studies.  
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This study is also limited by a lack of data on the precise (i.e. day to day) nutritional intake 
and overall health of the children. Investigation of these aspects may provide insight into the 
reasons why these children have progressive growth failure. Other studies suggest tiredness, 
taste fatigue, avoidance of foods that are difficult to swallow and poor appetite during 
respiratory infections all contribute to malnutrition (12,18).  Our study is restricted in scope 
to studying the key features of the growth trajectories of children with A-T in our clinic.  There 
are several areas that are ripe for future study, including the impact of puberty and sex 
hormones, and the impact of oromotor swallowing difficulties upon nutrition. The absence of 
a pubertal assessment in particular is an acknowledged weakness of the study. We plan to 
report on these in future papers.   
These clinical data confirm that there is progressive growth failure with increasing age in 
children with A-T. Particular attention to the nutrition of those over 8 years is essential, as 
this is when growth failure becomes apparent in the majority of children. Previous studies in 
A-T have shown that PEG insertion has very high levels of caregiver satisfaction and late PEG 
insertion is associated with adverse outcomes. We hypothesise that early intervention with 
PEG feeding for malnourished children is beneficial, ideally prior to significant growth failure, 
and our data are supportive of this.  Given the low patient numbers, a randomised controlled 
trial will not likely be possible.  However, we will continue to collect data within this national 
clinic, and we propose to carefully follow children to assess the efficacy of early PEG insertion 
(prior to significant growth failure) and other early nutritional interventions in A-T. 
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Table 1: Median age, Z-scores for weight, height and BMI and the number of measurements 
that were underweight, stunted or wasted. 
  
 
Table 2: Comparison of cases and controls in nested case/control study. 
 Cases Controls 
N 12 25 
Number Female (%) 5 (42%) 17 (68%) 
Age at baseline, 
Median [rangeIQR] 
10.7 [8.2 to 13.47.9 to 14.7] 9.1 [8.4 to 10.47.6 to 15.2] 
Duration of follow up, years 
Median [rangeIQR]  
2.43 [2.0 to 3.6 0.4 to 6.1] 2.6 [1.3 to 4.30.4 to 5.68] 
Baseline weight Z- score  
Mean (sd) 
-2.42 (1.64) -1.21 (1.091) 
Change in Z-score for weight 
per year  
Median [IQR] 
0.2 [-0.3 to 0.4] -0.2 [-0.4 to 0.0] 
Proportion (percent) of 
patients with increasing 
weight over time 
8 / 12 (67%) 8 / 25 (32%) 
 
 
 
  
 All visits Z-scores ≤ -
2.0 = N (% of 
total 
measureme
nts) 
Baseline 
N = 32 
Second visit 
N = 32 
Third visit 
N = 32 
Age in years 
(median and 
interquartile 
range) 
9.326 
(1.536.4 to 
1813.1.38) 
 8.3 
(1.54.3 to 
11.318.38) 
9.9710.0 
(6.84.3 to 
13.216.8) 
12.31  
(6.4 to 
117.75.5) 
Z-
scor
es 
(me
an 
and 
sd) 
Weigh
t 
-1.0329 
(1.657) 
 
59 (276.6%)  -0.97 (1.61) 
 
-0.95 (1.548) 
 
-1.33 (1.52) 
 
Heigh
t 
-1.217 
(1.218)  
 
47 (221.8%) -1.16 (1.326)  
 
-1.216 (1.14) 
 
-1.326 
(0.951.0) 
 
BMI -0.357 4 
(1.43) 
28 (133.0%) -0.31 (1.34) -0.30 (1.354) 
 
-0.78 8 
(1.875) 
 
Table 1 
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Figure 1. Scatter plots showing the trajectories of weight (A and B), height (C) and BMI (D).  
Individual patients’ trajectories are shown by joining points of measurement with a straight 
line. Only patients with multiple measurements are shown. If the patient did not have a PEG 
at the time of measurement, the point is a hollow circle, whereas the presence of a PEG is 
denoted with a filled black circle. Similarly lines are grey for patients who never had a PEG, 
but if a patient has ever had a PEG, then the line is black to allow identification of individual 
patients’ trajectories. Panel B shows only individuals who had a PEG in situ, to allow an 
appreciation of the trajectories for these patients.   
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